This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
5 Dividend ETFs Crushing the Market This Year
by Sweta Killa
The dividend-focused products offer safety through payouts and stability in the form of mature companies that are less volatile amid large swings in stock prices.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
An ETF Retirement Portfolio for 2022
by Sanghamitra Saha
What should a retiree do in a rocky investing environment like now? We highlight a few ETF strategies that could be considered in a retirement portfolio with a medium-term focus.
2 ETFs to Watch for Outsized Volume on Growth and Dividend
by Sanghamitra Saha
Large-cap growth ETF MGK and the dividend ETF FDL traded with an above-average volume on Friday.
The Zacks Analyst Blog Highlights iShares Select Dividend ETF, First Trust Morningstar Dividend Leaders Index Fund, iShares Core High Dividend ETF, Invesco S&P 500 High Dividend Low Volatility ETF and Fidelity High Dividend ETF
by Zacks Equity Research
iShares Select Dividend ETF, First Trust Morningstar Dividend Leaders Index Fund, iShares Core High Dividend ETF, Invesco S&P 500 High Dividend Low Volatility ETF and Fidelity High Dividend ETF have been included in this Analyst Blog.
Dividend ETFs Scaling New Highs
by Sweta Killa
Dividend investing has been in vogue amid bouts of volatility and uncertainty, pushing dividend ETFs to new highs.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Dividend ETFs At New Peaks Amid Volatility
by Sweta Killa
The appeal for dividend-focused ETFs is high at the start of 2022, given bouts of volatility triggered by a hawkish Fed, rising yields, skyrocketing inflation and of course a spike in the Omicron COVID-19 variant cases.
Pfizer ETFs to Rise on FDA's EUA for COVID-19 Oral Antiviral Pill
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the receipt of EUA for the antiviral COVID-19 pill.
5 Best-Performing ETFs of December
by Sweta Killa
A few are still in green with most of them from the defensive sectors like utilities, healthcare and consumer staples.